Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Stock Chart

Financials

Date Filing Description Download
10/11/17 4 Statement of Changes in Beneficial Ownership
09/27/17 8-K Current report filing
09/01/17 8-A12B Securities Registration (section 12(b))
09/01/17 8-K Current report filing

Stock Quote

ACOR (Common Stock) $ 27.20 +0.50 (+1.87%) Volume: 619,321 MORE October 20, 2017

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *





 
Enter the code shown above.